BACKGROUND: Animal models suggest that n-3 fatty acids inhibit prostate cancer proliferation, whereas n-6 fatty acids promote it, but epidemiologic studies do not uniformly support these findings. METHODS: A nested case-control study was conducted among 14,916 apparently healthy men who provided blood samples in 1982. Blood fatty acid levels were determined for 476 men diagnosed with prostate cancer during a 13-year follow-up and their matched controls. Conditional logistic regression was used to estimate the relative risks (RR) and 95% confidence intervals (95% CI) of total, non-aggressive (stage A/B and Gleason < 7) and aggressive (stage C/D, Gleason >or= 7, subsequent distant metastasis or death) prostate cancer associated with blood levels of specific fatty acids expressed as percentages of total fatty acids. RESULTS: Whole blood levels of all long-chain n-3 fatty acids examined and of linoleic acid were inversely related to overall prostate cancer risk (RR(Q5vs.Q1), 0.59; 95% CI, 0.38-0.93; P(trend) = 0.01 for total long-chain n-3 fatty acids and RR(Q5vs.Q1), 0.62; 95% CI, 0.41-0.95; P(trend) = 0.03 for linoleic). Blood levels of gamma-linolenic and dihomo-gamma-linolenic acids, fatty acids resulting from the metabolism of linoleic acid, were directly associated with prostate cancer (RR, 1.41; 95% CI, 0.94-2.12; P(trend) = 0.05 for gamma-linolenic and RR, 1.54; 95% CI, 1.03-2.30; P(trend) = 0.02 for dihomo-gamma-linolenic acid). Levels of arachidonic and alpha-linolenic acids were unrelated to prostate cancer. CONCLUSIONS: Higher blood levels of long-chain n-3 fatty acids, mainly found in marine foods, and of linoleic acid, mainly found in non-hydrogenated vegetable oils, are associated with a reduced risk of prostate cancer. The direct associations of linoleic acid metabolites with prostate cancer risk deserve further investigation.
RCT Entities:
BACKGROUND: Animal models suggest that n-3 fatty acids inhibit prostate cancer proliferation, whereas n-6 fatty acids promote it, but epidemiologic studies do not uniformly support these findings. METHODS: A nested case-control study was conducted among 14,916 apparently healthy men who provided blood samples in 1982. Blood fatty acid levels were determined for 476 men diagnosed with prostate cancer during a 13-year follow-up and their matched controls. Conditional logistic regression was used to estimate the relative risks (RR) and 95% confidence intervals (95% CI) of total, non-aggressive (stage A/B and Gleason < 7) and aggressive (stage C/D, Gleason >or= 7, subsequent distant metastasis or death) prostate cancer associated with blood levels of specific fatty acids expressed as percentages of total fatty acids. RESULTS: Whole blood levels of all long-chain n-3 fatty acids examined and of linoleic acid were inversely related to overall prostate cancer risk (RR(Q5vs.Q1), 0.59; 95% CI, 0.38-0.93; P(trend) = 0.01 for total long-chain n-3 fatty acids and RR(Q5vs.Q1), 0.62; 95% CI, 0.41-0.95; P(trend) = 0.03 for linoleic). Blood levels of gamma-linolenic and dihomo-gamma-linolenic acids, fatty acids resulting from the metabolism of linoleic acid, were directly associated with prostate cancer (RR, 1.41; 95% CI, 0.94-2.12; P(trend) = 0.05 for gamma-linolenic and RR, 1.54; 95% CI, 1.03-2.30; P(trend) = 0.02 for dihomo-gamma-linolenic acid). Levels of arachidonic and alpha-linolenic acids were unrelated to prostate cancer. CONCLUSIONS: Higher blood levels of long-chain n-3 fatty acids, mainly found in marine foods, and of linoleic acid, mainly found in non-hydrogenated vegetable oils, are associated with a reduced risk of prostate cancer. The direct associations of linoleic acid metabolites with prostate cancer risk deserve further investigation.
Authors: Theodore M Brasky; Cathee Till; Emily White; Marian L Neuhouser; Xiaoling Song; Phyllis Goodman; Ian M Thompson; Irena B King; Demetrius Albanes; Alan R Kristal Journal: Am J Epidemiol Date: 2011-04-24 Impact factor: 4.897
Authors: Meng Yang; Azalea Ayuningtyas; Stacey A Kenfield; Howard D Sesso; Hannia Campos; Jing Ma; Meir J Stampfer; Jorge E Chavarro Journal: Cancer Causes Control Date: 2016-08-03 Impact factor: 2.506
Authors: Sarah H Nash; Jeannette M Schenk; Alan R Kristal; Phillis J Goodman; M Scott Lucia; Howard L Parnes; Ian M Thompson; Scott M Lippman; Xiaoling Song; Bora Gurel; Angelo De Marzo; Elizabeth A Platz Journal: Cancer Prev Res (Phila) Date: 2015-04-29
Authors: Ting-Yuan David Cheng; Irena B King; Matt J Barnett; Christine B Ambrosone; Mark D Thornquist; Gary E Goodman; Marian L Neuhouser Journal: Am J Epidemiol Date: 2013-03-27 Impact factor: 4.897
Authors: Song-Yi Park; Lynne R Wilkens; Susanne M Henning; Loïc Le Marchand; Kun Gao; Marc T Goodman; Suzanne P Murphy; Brian E Henderson; Laurence N Kolonel Journal: Cancer Causes Control Date: 2008-09-27 Impact factor: 2.506
Authors: Subreen A Khatib; Emily L Rossi; Laura W Bowers; Stephen D Hursting Journal: Prostaglandins Other Lipid Mediat Date: 2016-07-19 Impact factor: 3.072
Authors: Srinivas Pentyala; Terry Whyard; Sahana Pentyala; John Muller; John Pfail; Sunjit Parmar; Carlos G Helguero; Sardar Khan Journal: Biomed Rep Date: 2016-01-29